Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
Items 201–300 of 1,000
Kasai, T., Iwanaga, Y., Iha, H., & Jeang, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110295200 · Cited by 113
p53-mediated apoptosis requires inositol hexakisphosphate kinase-2
Koldobskiy, M. A., Chakraborty, A., Werner, J. K., Snowman, A. M., Juluri, K. R., Vandiver, M. S., Kim, S., Heletz, S., & Snyder, S. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015671107 · Cited by 111
“The prominent anticancer drug 5-fluorouracil (5-FU) kills cells selectively through the p53 pathway (16).”
BackgroundExpression of Androgen Receptor Is Negatively Regulated By p53
Alimirah, F., Panchanathan, R., Chen, J., Zhang, X., Ho, S.-M., & Choubey, D. (2007) · Neoplasia · doi:10.1593/neo.07769 · Cited by 108
“HCT116 p53 wild-type and p53 knockout colorectal carcinoma cells [26] were generously provided by Dr.”
BackgroundMethodTumour suppressor genes in chemotherapeutic drug response
Lai, D., Grieve, S., & Yang, X. (2012) · Bioscience Reports · doi:10.1042/bsr20110125 · Cited by 126
Arango, D., Corner, G. A., Wadler, S., Catalano, P. J., & Augenlicht, L. H. (2001) · PubMed · Cited by 121
Green, S. K., Francia, G., Isidoro, C., & Kerbel, R. S. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.149.3.2 · Cited by 107
“mised p53 activity to arrest in a single peak spanning the G1-S boundary (36) or fully in S phase (37, 38).”
BackgroundKrüppel-like factor 4 exhibits antiapoptotic activity following γ-radiation-induced DNA damage
Ghaleb, A. M., Katz, J. P., Kaestner, K. H., Du, J. X., & Yang, V. W. (2006) · Oncogene · doi:10.1038/sj.onc.1210022 · Cited by 125
“, 1993a, b) and cancerous cells (Bunz et al., 1999).”
TP53 Status and Response to Chemotherapy in Breast Cancer
Bertheau, P., Espié, M., Turpin, E., Lehmann, J., Plassa, L.-F., Varna, M., Janin, A., & de Thé, H. (2008) · Pathobiology · doi:10.1159/000123851 · Cited by 108
“referred to p53 as a ‘double-edged sword’. In the same journal issue, Bunz et al. [”
BackgroundLi, W., Du, B., Wang, T., Wang, S., & Zhang, J. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.10.048 · Cited by 119
Wohak, L. E., Krais, A. M., Kucab, J. E., Stertmann, J., Øvrebø, S., Seidel, A., Phillips, D. H., & Arlt, V. M. (2016) · Archives of Toxicology · doi:10.1007/s00204-014-1409-1 · Cited by 104
“It has been shown that reductions in p53 dosage and function can impact on a cell’s ability to respond to DNA damage (Berger et al. 2011; Bunz et al. 1999).”
BackgroundGielecińska, A., Kciuk, M., Yahya, E. B., Ainane, T., Mujwar, S., & Kontek, R. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189024 · Cited by 123
Jung, H., Seong, H.-A., & Ha, H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800050200 · Cited by 106
Yang, W., Addona, T., Nair, D. G., Qi, L., & Ravikumar, T. S. (2002) · International Journal of Cancer · doi:10.1002/ijc.10822 · Cited by 108
Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
Lambert, J. M. R., Moshfegh, A., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2010) · Oncogene · doi:10.1038/onc.2009.425 · Cited by 106
“…suppressor activity as well as the acquisition of novel functions (so called gain-of-function) attributed to some p53 mutants, often counteracts the effect of cancer treatment, as many anti-cancer drugs attack tumors by activating p53-dependent apoptosis (Bunz et al., 1999; Andersson et al., 2005).”
BackgroundLiao, C., Sang, S., Ho, C., & Lin, J. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20540 · Cited by 111
“Recently, a standard chemotherapeutic agent, 5-fluorouracil, has been improved to induce apoptosis in colorectal cancer with biochemical modification [Bunz et al., 1999].”
BackgroundRole of Apoptosis in Colon Cancer Biology, Therapy, and Prevention
Zhang, L., & Yu, J. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0188-z · Cited by 123
Peták, I., Tillman, D. M., & Houghton, J. A. (2000) · PubMed · Cited by 106
Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., Christen, R. D., & Howell, S. B. (2001) · PubMed · Cited by 106
Cheteh, E. H., Sarne, V., Ceder, S., Bianchi, J., Augsten, M., Rundqvist, H., Egevad, L., Östman, A., & Wiman, K. G. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0272-5 · Cited by 104
NM23-H1 Tumor Suppressor and Its Interacting Partner STRAP Activate p53 Function
Jung, H., Seong, H., & Ha, H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705181200 · Cited by 105
Review of Prodigiosin, Pigmentation in Serratia marcescens
Khanafari, A., Assadi, M. M., & Fakhr, F. A. (2006) · OnLine Journal of Biological Sciences · doi:10.3844/ojbsci.2006.1.13 · Cited by 105
Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment
Ungerleider, N., Rao, S. G., Shahbandi, A., Yee, D., Niu, T., Frey, W. D., & Jackson, J. G. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1044-5 · Cited by 117
Meslin, B., Barnadas, C., Boni, V., Latour, C., de Monbrison, F., Kaiser, K., & Picot, S. (2007) · The Journal of Infectious Diseases · doi:10.1086/518253 · Cited by 121
“This can be demonstrated by the fact that cancer cells that have become resistant to chemotherapies and lack the ability to undergo apoptosis have done so using a multitude of various pathways, including mutation of key checkpoint regulators, overexpression of Bcl-2 family, or disruption of mitochondrial-mediated apop…”
BackgroundKuete, V., Tankeo, S. B., Saeed, M. E. M., Wiench, B., Tane, P., & Efferth, T. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.02.025 · Cited by 104
Mohapatra, P., Preet, R., Das, D., Satapathy, S. R., Choudhuri, T., Wyatt, M. D., & Kundu, C. N. (2012) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504012x13473664562628 · Cited by 116
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy
Benkafadar, N., Menardo, J., Bourien, J., Nouvian, R., François, F., Decaudin, D., Maiorano, D., Puel, J., & Wang, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606230 · Cited by 112
“Alternatively, inhibiting the protective role of p53 in inducing growth arrest and DNA repair would increase the risk of mitotic catastrophe in tumor stromal cells (Bunz et al, 1999; Komarova et al, 2004).”
BackgroundSohn, D., Graupner, V., Neise, D., Eßmann, F., Schulze‐Osthoff, K., & Jänicke, R. U. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.17 · Cited by 117
Murase, D., Hachiya, A., Amano, Y., Ohuchi, A., Kitahara, T., & Takema, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805570200 · Cited by 104
Kashima, L., Idogawa, M., Mita, H., Shitashige, M., Yamada, T., Ogi, K., Suzuki, H., Toyota, M., Ariga, H., Sasaki, Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.321828 · Cited by 103
Licitra, L. F., Suardi, S., Bossi, P., Locati, L. D., Mariani, L., Quattrone, P., Vullo, S. L., Oggionni, M., Olmi, P., Cantù, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.071 · Cited by 112
Wu, G. S., & Ding, Z. (2002) · Oncogene · doi:10.1038/sj.onc.1205020 · Cited by 113
“The human colon cancer cell lines HCT116 p53+/+ andHCT116 p537/7, a generous gift fromDr Bert Vogelstein (Johns Hopkins University, Baltimore, MD, USA), were maintained in McCoy's media as described (Bunz et al., 1999).”
BackgroundMethodResultInfluentialRavi, R. K., & Bedi, A. (2002) · PubMed · Cited by 115
Allen, J. E., Krigsfeld, G. S., Patel, L., Mayes, P. A., Dicker, D. T., Wu, G. S., & El‐Deiry, W. S. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0346-9 · Cited by 101
“We explicitly selected for TRAIL-inducing compounds that upregulate TRAIL gene transcription using a mechanism that does not rely on p53 due to its frequent inactivation in late stage cancers that causes resistance to many standard-of-care therapies [24].”
BackgroundPUMA Sensitizes Lung Cancer Cells to Chemotherapeutic Agents and Irradiation
Yu, J., Yue, W., Wu, B., & Zhang, L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2429 · Cited by 108
Modulating apoptosis as a target for effective therapy
Fleischer, A., Ghadiri, A., Dessauge, F., Duhamel, M., Rebollo, M. P., Alvarez-Franco, F., & Rebollo, A. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.013 · Cited by 108
Ray, R. M., Bhattacharya, S., & Johnson, L. R. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0538-0 · Cited by 108
“Several recent studies have shown that the p53 status influences the response of tumor cells to DNA damaging agents [22, 23].”
BackgroundLongley, D. B., Boyer, J. D., Allen, W. L., Latif, T., Ferguson, P., Maxwell, P. J., McDermott, U., Lynch, M., Harkin, D. P., & Johnston, P. G. (2002) · PubMed · Cited by 120
Pugacheva, E. N., Ivanov, A. V., Kravchenko, J. E., Kopnin, B. P., Levine, A. J., & Chumakov, P. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205704 · Cited by 101
“In several cases such effects of p53 mutants were attributed to dominant-negative suppression of the wild type p53 activity that resulted in abrogation of p53-induced apoptosis (Bunz et al., 1999), and an increase in activity of the MDR1 gene (Bottini et al., 2000).”
BackgroundKerley-Hamilton, J. S., Pike, A. M., Li, N., DiRenzo, J., & Spinella, M. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208755 · Cited by 114
“Since it has been convincingly shown that in certain tumor contexts p53 protects cells from cisplatin toxicity due to induction of G1 arrest (Bunz et al., 1999), the role of p53 in TGCT response remains controversial, and important pathways downstream of p53 remain poorly understood.”
BackgroundApoptosis in human cancer cells
Yu, J., & Zhang, L. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200401000-00005 · Cited by 107
p53 Maintains Genomic Stability by Preventing Interference between Transcription and Replication
Yeo, C. Q. X., Alexander, I., Lin, Z., Lim, S., Aning, O. A., Kumar, R., Sangthongpitag, K., Pendharkar, V., Ho, V. H. B., & Cheok, C. F. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.011 · Cited by 99
“…indicate SD. cells arises during replication, and the role that wild-type p53 plays in protecting against Topo II inhibition during the S phase is independent of its described G2 checkpoint function in preventing mitotic entry and chromosomal breaks (Bunz et al., 1998, 1999; Nghiem et al., 2001).”
BackgroundResultInfluentialMullally, J. E., & Fitzpatrick, F. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.2.351 · Cited by 106
“However, numerous investigations show that disruption of p53 impairs the potency and efficacy of drugs used in oncology [e.g., 5-fluorouracil (Lowe et al., 1994, 1995; Mueller and Eppenberger, 1996; O’Connor et al., 1997; Bunz et al., 1999; Pich, 1998; Weller, 1998; Karpf et al., 2001)].”
Background5-Fluorouracil Enhances Exosome-Dependent Accumulation of Polyadenylated rRNAs
Fang, F., Hoskins, J., & Butler, J. S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10766-10776.2004 · Cited by 93
p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?
Levesque, A. A., & Eastman, A. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl214 · Cited by 95
Adjei, A. A., Davis, J. N., Bruzek, L. M., Erlichman, C., & Kaufmann, S. H. (2001) · PubMed · Cited by 105
Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil
Calviello, G., Nicuolo, F. D., Serini, S., Piccioni, E., Boninsegna, A., Maggiano, N., Ranelletti, F. O., & Palozza, P. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0846-6 · Cited by 94
“human colon cancer cells [10], we analyzed the effects of”
BackgroundThe Role of Mitogen-Activated Protein Kinase Phosphatase-1 in Oxidative Damage–Induced Cell Death
Zhou, J.-Y., Liu, Y., & Wu, G. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4229 · Cited by 94
p53 and IGFBP-3: Apoptosis and Cancer Protection
Grimberg, A. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3008 · Cited by 105
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations
Funk, J. S., Klimovich, M., Drangenstein, D., Pielhoop, O., Hunold, P., Borowek, A., Noeparast, M., Pavlakis, E., Neumann, M., Balourdas, D.-I., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02039-4 · Cited by 103
Hypoxia attenuates the p53 response to cellular damage
Achison, M., & Hupp, T. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206434 · Cited by 107
“HCT116 human colorectal carcinoma cell lines (p53+/+ and p53 / ) were a kind gift of Dr Bert Vogelstein (Waldman et al., 1995; Bunz et al., 1999) (Johns Hopkins University, USA) and maintained in a monolayer culture in McCoys 5A modified medium (GibcoBRL, 26600-023) supplemented with 10% foetal…”
BackgroundMethodInfluentialRoh, J.-L., Kang, S. K., Minn, I., Califano, J. A., Sidransky, D., & Koch, W. M. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2010.10.011 · Cited by 93
Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage
Wu, Z., Lee, S. T., Qiao, Y., Li, Z., Lee, P. L., Lee, Y. J., Jiang, X., Tan, J. Y., Aau, M., Lim, C. Z. H., et al. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.48 · Cited by 95
Hippo pathway mediates resistance to cytotoxic drugs
Gujral, T. S., & Kirschner, M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703096114 · Cited by 91
“Similarly, p53 disruption rendered colorectal cancer cells resistant to the antimetabolite 5-FU but sensitized these cells to the DNA-damaging drug doxorubicin (52).”
BackgroundGrassilli, E., Narloch, R., Federzoni, E., Ianzano, L., Pisano, F., Giovannoni, R., Romano, G., Masiero, L., Leone, B. E., Bonin, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3289 · Cited by 93
“Based on these premises, we conducted a phenotype screen using the kinase pools of the NKI short hairpin RNA (shRNA) library (7) and 5-fluorouracil (5FU)-resistant HCT116p53KO cells (8) as a model.”
BackgroundMethodOncogenic resistance to growth-limiting conditions
Blagosklonny, M. V. (2002) · Nature reviews. Cancer · doi:10.1038/nrc743 · Cited by 92
“asp?DrugCode=A%2D3907&DrugName=FLUOROURACIL+INTRAVEN%2E&DrugType=1">5-fluorouracil”
Prediction of the response of colorectal cancer to systemic therapy
Adlard, J., Richman, S. D., Seymour, M., & Quirke, P. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00648-4 · Cited by 97
Hayward, R. L., Macpherson, J. S., Cummings, J., Monia, B. P., Smyth, J. F., & Jodrell, D. I. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.169.3.2 · Cited by 102
Oberst, M. D., Fuhrmann, S., Mulgrew, K., Amann, M., Cheng, L., Lutterbuese, P., Richman, L., Coats, S., Baeuerle, P. A., & Hammond, S. A. (2014) · mAbs · doi:10.4161/19420862.2014.975660 · Cited by 89
“However, the results of several studies suggest that the mutational status of TP53 may modulate the response of cancers to molecularly targeted agents, even if the agents are not designed to target the TP53 pathway directly.(22) For example, mutant TP53 is a predictor of better clinical outcome in patients with chemot…”
ResultCarcinogenesis, cancer therapy and chemoprevention
Blagosklonny, M. V. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401610 · Cited by 104
“Also, p53 disruption sensitizes certain cells to DNA-damaging agents, but renders these cells resistant to the antimetabolite 5-fluorouracil.(109) As another example, activation of S-phase checkpoint and induction of E2F1 render cancer cells hypersensitive to lapachone.”
BackgroundRole of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells
Mahyar-Roemer, M., Köhler, H., & Roemer, K. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-27 · Cited by 100
“Although this cell cycle arrest is also reversible, cells with altered cell cycle checkpoints can be more prone to apoptotic death [14,15,18].”
BackgroundStoichiometric Phosphorylation of Human p53 at Ser315Stimulates p53-dependent Transcription
Blaydes, J. P., Luciani, M. G., Pospisilova, S., Ball, H. M.-L., Vojtesek, B., & Hupp, T. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m003485200 · Cited by 90
DNA Damage-induced Inhibition of Securin Expression Is Mediated by p53
Zhou, Y., Mehta, K. R., Choi, A., Scolavino, S., & Zhang, X. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203793200 · Cited by 98
Neznanov, N., Komarov, A. P., Neznanova, L., Stanhope-Baker, P., & Gudkov, A. V. (2011) · Oncotarget · doi:10.18632/oncotarget.246 · Cited by 92
“To examine the involvement of p53 in EPS-induced cytotoxicity, we used isogenic p53-/- and p53 wild type HCT116 cell lines [22] and compared the effects of nutlin-3a, an MDM2 inhibitor that specifically prevents p53 degradation [23,24], with those of bortezomib.”
MethodResistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.
Geretto, M., Pulliero, A., Rosano, C., Zhabayeva, D., Bersimbaev, R. I., & Izzotti, A. (2017) · PubMed Central · Cited by 108
Cell Cycle Regulation and p53 Activation by Protein Phosphatase 2Cα
Ofek, P., Ben‐Meir, D., Kariv-Inbal, Z., Oren, M., & Lavi, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211699200 · Cited by 115
Pyrko, P., Soriano, N., Kardosh, A., Liu, Y., Uddin, J., Petasis, N. A., Hofman, F. M., Chen, C., Chen, T. C., & Schönthal, A. H. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-19 · Cited by 100
Kitzen, J. J. E. M., de Jonge, M. J. A., Lamers, C. H. J., Eskens, F. A. L. M., van der Biessen, D., van Doorn, L., ter Steeg, J., Brandely, M., Puozzo, C., & Verweij, J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.01.026 · Cited by 89
Regulation and Functional Contribution of Thymidine Kinase 1 in Repair of DNA Damage
Chen, Y., Eriksson, S., & Chang, Z.-F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.137042 · Cited by 111
Li, J. Z., Wood, W. H., Becker, K. G., Weeraratna, A. T., & Morin, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1210086 · Cited by 98
“, 2002) and other chemotherapeutic drugs (Hawkins et al., 1996; Bunz et al., 1999).”
Growth Factor-Mediated Induction of HDM2 Positively Regulates Hypoxia-Inducible Factor 1α Expression
Bárdos, J. I., Chau, N.-M., & Ashcroft, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2905-2914.2004 · Cited by 87
“HCT116 matched human colorectal cell lines have been described previously (8).”
BackgroundLam, T. L., Wong, G., Chong, H.-C., Cheng, P. N.-M., Choi, S. C., Chow, T. L., Kwok, S.-Y., Poon, R. T. P., Wheatley, D. N., Lo, W., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.11.031 · Cited by 93
“However, it has been shown to be ineffective against cancer cells which do not express wild type p53 [50].”
BackgroundFábián, Z., Csatary, C. M., Szeberényi, J., & Csatáry, L. K. (2007) · Journal of Virology · doi:10.1128/jvi.02490-06 · Cited by 89
“Since the primary target for current chemo- and radiotherapies is the genomic DNA, and since DNA damage induces p53-dependent apoptosis, the p53 status of the cancer cell has a fundamental effect on the outcome of anticancer treatments (8, 28).”
BackgroundIncreased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer
Turpin, E., Bièche, I., Bertheau, P., Plassa, L., Lerebours, F., de Roquancourt, A., Olivi, M., Espié, M., Marty, M. E., Lidereau, R., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205932 · Cited by 87
“Identification of these subjects would be extremely important to obtain molecular/ clinical correlates, as was recently suggested for colon cancer in a study of the response to 5-FU by patients with microsatellite instability (MSI) and non-MSI tumours (Bunz et al., 1999; Elsaleh et al., 2000).”
BackgroundAl-Aamri, H. M., Ku, H., Irving, H. R., Tucci, J., Meehan-Andrews, T., & Bradley, C. (2019) · BMC Cancer · doi:10.1186/s12885-019-5377-y · Cited by 90
p53 Promotes Cell Survival due to the Reversibility of Its Cell-Cycle Checkpoints
Lukin, D. J., Carvajal, L. A., Liu, W.-J., Resnick‐Silverman, L., & Manfredi, J. J. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0177 · Cited by 92
“These data are consistent with those of (4) and established the mechanism of cell death in the p53-ablated cells as apoptosis.”
Boya, P., Morales, M., González‐Polo, R. A., Andréau, K., Gourdier, I., Perfettini, J., Larochette, N., Deniaud, A., Baran‐Marszak, F., Fagard, R., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206827 · Cited by 94
“In a further series of experiments, we compared the effect of 4-HPR on HCT-116 colon carcinoma cells that express p53 or lack p53 expression as a result of homologous recombination (Bunz et al., 1999).”
BackgroundPromotion of autophagy as a mechanism for radiation sensitization of breast tumor cells
Gewirtz, D. A., Bristol, M. L., & Wilson, E. N. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.05.022 · Cited by 97
Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo
Zhao, X., & Yu, Y.-T. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl1084 · Cited by 94
Ceilley, R. I. (2010) · Journal of Dermatological Treatment · doi:10.3109/09546634.2010.507704 · Cited by 85
“This suggests that p53 is involved in cell-cycle arrest and apoptosis in cells treated with 5-FU (24).”
BackgroundLin, X., & Howell, S. B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0491 · Cited by 83
“The hMLH1deficient HCT116 was obtained from the American Type Culture Collection (Manassas, VA); HCT116 contains a hemizygous mutation in hMLH1 resulting in a truncated, nonfunctional protein (16) but is proficient in p53 function (17, 18).”
MethodZhang, L.-N., Li, J., & Xu, W. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.84 · Cited by 98
Yao, K., Gietema, J. A., Shida, S., Selvakumaran, M., Fonrose, X., Haas, N. B., Testa, J., & O'Dwyer, P. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602864 · Cited by 82
“A similar procedure was followed to derive hypoxia-conditioned cells from HCT116/p53 / , a p53-knockout cell line that has been well characterized in previous studies (Bunz et al, 1999).”
MethodResultRole of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin
Ravizza, R., Gariboldi, M. B., Passarelli, L., & Monti, E. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-92 · Cited by 94
“In a number of studies, p21 has actually been reported to protect tumor cells against cell death induced by enforced p53 expression [26] or by low doses of cytotoxic agents [13,27-30].”
BackgroundDaoud, S. S., Munson, P. J., Reinhold, W. C., Young, L., Prabhu, V. V., Yu, Q., Rose, J. H. L., Kohn, K. W., Weinstein, J. N., & Pommier, Y. G. (2003) · PubMed · Cited by 82
Hernández‐Vargas, H., Ballestar, E., Carmona‐Sáez, P., von Kobbe, C., Bañón‐Rodríguez, I., Esteller, M., Moreno‐Bueno, G., & Palacios, J. (2006) · International Journal of Cancer · doi:10.1002/ijc.21938 · Cited by 83
“There is compelling evidence that one of its main effectors is p53, known as an important mediator in the action of many other drugs and DNA damaging agents.(27,28) In fact, previous reports have demonstrated a correlation between 5FU treatment and changes in p53 and p53 target molecules.”
BackgroundMismatch repair and response to DNA-damaging antitumour therapies
Bignami, M., Casorelli, I., & Karran, P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00569-0 · Cited by 89
“This differential sensitivity is also apparent in xenografts [21].”
BackgroundPharmacogenomics of 5-fluorouracil in colorectal cancer: review and update
Xie, P., Mo, J., Liu, J., Li, X., Tan, L., Zhang, W., Zhou, H., & Liu, Z. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00529-1 · Cited by 85
Chapter 3 The TRAIL to Targeted Therapy of Breast Cancer
Rahman, M., Pumphrey, J. G., & Lipkowitz, S. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)03003-6 · Cited by 97
“In cancer cells, the mutation or absence of p53 renders cells resistant to chemotherapy or radiation therapy (Bunz et al., 1999; Lee and Bernstein, 1993; Lowe et al., 1993, 1994).”
BackgroundDemoulin, B., Hermant, M., Castrogiovanni, C., Staudt, C., & Dumont, P. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.04.015 · Cited by 83
Ott, K., Vogelsang, H., Mueller, J., Becker, K., Müller, M., Fink, U., Siewert, J. R., Höfler, H., & Keller, G. (2003) · PubMed · Cited by 87
Hayward, R. L., Schornagel, Q. C., Tente, R., Macpherson, J. S., Aird, R. E., Guichard, S. M., Habtemariam, A., Sadler, P. J., & Jodrell, D. I. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0932-9 · Cited by 95
“In general, two competing p53mediated responses to cytotoxics are observed, namely cell death and cell cycle arrest [10, 11].”
BackgroundCyclotherapy: Protection of Normal Cells and Unshielding of Cancer Cells
Blagosklonny, M. V., & Darzynkiewicz, Z. (2002) · Cell Cycle · doi:10.4161/cc.1.6.259 · Cited by 79
Curcumin induces apoptosis in HCT-116 human colon cancer cells in a p21-independent manner
Watson, J. L., Hill, R., Lee, P. W. K., Giacomantonio, C. A., & Hoskin, D. W. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.02.002 · Cited by 79
p53 and p21 Determine the Sensitivity of Noscapine-Induced Apoptosis in Colon Cancer Cells
Aneja, R., Ghaleb, A. M., Zhou, J., Yang, V. W., & Joshi, H. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4282 · Cited by 87
“In some settings, p53 loss can enhance drug-induced apoptotic cell death (12) and its loss correlates with”
BackgroundRestoring p53-mediated apoptosis in cancer cells: New opportunities for cancer therapy
Yu, Q. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.03.001 · Cited by 87
“It has been thought that p53 ells, activation of p53 leads to apoptosis in response to the enotoxic agent 5-fluorouracil (5-FU), but to cell cycle arrest n response to adriamycin (Bunz et al., 1999).”
BackgroundGourdier, I., Crabbé, L., Andréau, K., Pau, B., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1208047 · Cited by 91
“The HCT116/p53 / and HCT116/ Bax / cell lines, as well as their controls, were kindly provided by Dr B Vogelstein (Bunz et al., 1999; Zhang et al., 2000). pGL2B-mdm2-luciferase and pTKRL plasmids were a generous gift from Dr P Roux.”
MethodSmall-Molecule Inhibitors of the p53-MDM2 Interaction
Vu, B. T., & Vassilev, L. T. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_110 · Cited by 87
“The cell cycle arrest function of p53 plays an important role in protection from cancer by helping the repair machinery to complete its function before cells enter into replication or mitosis ( Bunz et al. 1999; Xiong et al. 1993).”
Backgroundp53 Activity Results in DNA Replication Fork Processivity
Klusmann, I., Rodewald, S., Müller, L., Friedrich, M., Wienken, M., Li, Y., Schulz‐Heddergott, R., & Dobbelstein, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.036 · Cited by 86
Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation
Forrest, R. A., Swift, L. P., Rephaeli, A., Nudelman, A., Kimura, K., Phillips, D. R., & Cutts, S. M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.02.026 · Cited by 92
Voorneveld, P. W., Kodach, L. L., Jacobs, R. J., van Noesel, C. J. M., Peppelenbosch, M. P., Korkmaz, K., Molendijk, I., Dekker, E., Morreau, H., van Pelt, G. W., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.560 · Cited by 94
“The inactivation of p53 has also been shown to result in a poorer response to chemotherapy in vivo (Lowe et al, 1994) and in vitro (Bunz et al, 1999), although some reports show otherwise(Hawkins et al, 1996).”
Result
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.